Area of research
Hematology · Cancer Research
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Cancer Genomics and Diagnostics, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)
Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis
Identification of a gene expression signature associated with brain metastasis in colorectal cancer
Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse
Treosulfan-Versus Melphalan-Based Reduced Intensity Conditioning in HLA-Haploidentical Transplantation for Patients ≥ 50 Years with Advanced MDS/AML
Pyjacker identifies enhancer hijacking events in acute myeloid leukemia including <i>MNX1</i> activation via deletion 7q
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
The evolving landscape of <scp>COVID</scp>‐19 and <scp>post‐COVID</scp> condition in patients with chronic lymphocytic leukemia: A study by <scp>ERIC</scp>, the <scp>European</scp> research initiative on <scp>CLL</scp>
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer
CSF3R T618I Collaborates With RUNX1-RUNX1T1 to Expand Hematopoietic Progenitors and Sensitizes to GLI Inhibition
Lysosomal Membrane Permeabilization Sensitizes Ctss-Hyperactive Tumors to BCL2-Targeting Therapies
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome
Risk Stratification of Patients with <i>RUNX1-</i>mutated Acute Myeloid Leukemia
Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML
<scp>HERVs</scp> characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance
Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
Specific effects of somatic GATA2 zinc finger mutations on erythroid differentiation